8-K current report · filed Oct 8, 2026

ANGIODYNAMICS INC (ANGO) 8-K Current Report: October 8, 2026

Item 1.01Item 5.02Item EX-99.1ANGO overview

Short answer

ANGIODYNAMICS INC (ANGO) filed an 8-K current report with the SEC on October 8, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Eric Honroth appointed President and Chief Executive Officer under employment agreement dated October 3, 2026.

ANGIODYNAMICS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Eric Honroth appointed President and Chief Executive Officer under employment agreement dated October 3, 2026
  • Leadership transition creates potential strategic and operational impact for AngioDynamics
  • Compensation, incentives and termination terms detailed in Item 5.02 and Exhibit 10.1

Item 5.02 · Departure/Election of Directors or Officers

  • CEO transition effective November 2, 2026: Eric Honroth succeeds James Clemmer after Clemmer’s retirement
  • Honroth brings Getinge, Abbott Vascular, Becton Dickinson, CareFusion and Boston Scientific leadership experience
  • Honroth compensation: $735,000 salary, 95% bonus target, $1,487,116 equity grant, $450,000 replacement award and $350,000 sign-on bonus
  • Severance exposure: 18 months’ salary and benefits, with 24 months’ salary plus accelerated equity after qualifying change-in-control termination
  • Clemmer receives $30,000 monthly consulting fees for up to 12 months, while Howard Donnelly retires after serving as director since 2004

Item EX-99.1 · Exhibit EX-99.1

  • Eric Honroth appointed President, CEO, and director effective November 2, 2026
  • Jim Clemmer retiring after 10 years as CEO, leaving the Board but continuing as a transition consultant
  • Honroth brings more than 20 years of medical technology leadership across cardiovascular, endovascular, urology, and oncology markets
  • Leadership transition targets sustainable revenue growth, margin expansion, and operational execution
  • Company enters transition with a high-growth Med Tech segment and no outstanding debt

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ANGIODYNAMICS INC 8-K filings

Get the next ANGO 8-K as it lands

Follow ANGO for push alerts, or ask the research agent what this filing means.